Friday, March 17, 2006

March 20, 2006, 10-11am [HMB13.356]: follicular lymphoma biomarkers, a classic

"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells." by Sandeep S. Dave, ..., Louis M. Staut, in N Engl J Med. 2004 Nov 18;351(21):2159-69 is our first entry. The presenter will be Li Zhang who will start the new biomarker journal club series with a classic.

Here's the abstract to spike your interest:

Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival.
Gene-expression profiling was performed on 191 biopsy specimens obtained from patients with untreated follicular lymphoma. Supervised methods were used to discover expression patterns associated with the length of survival in a training set of 95 specimens. A molecular predictor of survival was constructed from these genes and validated in an independent test set of 96 specimens.
Individual genes that predicted the length of survival were grouped into gene-expression signatures on the basis of their expression in the training set, and two such signatures were used to construct a survival predictor. The two signatures allowed patients with specimens in the test set to be divided into four quartiles with widely disparate median lengths of survival (13.6, 11.1, 10.8, and 3.9 years), independently of clinical prognostic variables. Flow cytometry showed that these signatures reflected gene expression by nonmalignant tumor-infiltrating immune cells.
The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.

Next meeting is April 3rd. The paper is not set yet so send your suggestions.


Blogger Jonas Almeida said...

Li Zhang, you need to change that picture of yours in your dept web page ...

6:12 AM  

Post a Comment

<< Home